Rep. Charles J. "Chuck" Fleischmann sold Solventum (SOLV)
Rep. Charles J. "Chuck" Fleischmann (R-TN-3) · $1K–$15K · traded Jul 8, 2024
- Transaction
- Sold
- Amount
- $1K–$15K
- Owner
- Joint
- Traded
- Jul 8, 2024
- Disclosed
- Aug 16, 2024
- Days to disclose
- 39
- Asset type
- Stock
- As filed
- Solventum Corp
- Industry
- Medical - Instruments & Supplies · Healthcare
Other trades in this filing
- Aug 16, 2024$1K–$15K
Bought State Street SPDR Portfolio High Yield Bond ETF SPHY
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$15K–$50K
Bought State Street SPDR S&P 400 Mid Cap Growth ETF MDYG
$15K–$50K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
Sold State Street SPDR Portfolio S&P 500 Value ETF SPYV
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
Bought State Street SPDR Portfolio S&P 500 Growth ETF SPYG
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
Sold State Street SPDR S&P 600 Small Cap Growth ETF SLYG
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$15K–$50K
Sold Pacer US Small Cap Cash Cows ETF CALF
$15K–$50K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
Sold iShares BB Rated Corporate Bond ETF HYBB
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
Sold iShares 1-5 Year Investment Grade Corporate Bond ETF IGSB
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
Bought Invesco S&P SmallCap Quality ETF XSHQ
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
Bought Invesco S&P MidCap Quality ETF XMHQ
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
Bought BondBloxx Bloomberg One Year Target Duration US Treasury ETF XONE
$1K–$15K · Traded Jul 16, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
$1K–$15K · Traded Jul 9, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$1K–$15K
$1K–$15K · Traded Jul 9, 2024 · disclosed Aug 16, 2024 · Joint
- Aug 16, 2024$15K–$50K
Bought William Blair Large Cap Growth Fund Class I LCGFX
$15K–$50K · Traded Jul 8, 2024 · disclosed Aug 16, 2024 · Joint
Recent Congress trades in SOLV
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Jan 23, 2026$15K–$50K
Rep. J. French Hill (R-AR-2)
$15K–$50K · Traded Dec 31, 2025 · disclosed Jan 23, 2026
- Feb 21, 2025$1K–$15K
Sen. Ron Wyden (D-OR)
$1K–$15K · Traded Feb 6, 2025 · disclosed Feb 21, 2025 · Spouse
- Feb 12, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Jan 15, 2025 · disclosed Feb 12, 2025 · Joint
- Jun 14, 2024$1K–$15K
Sen. Tommy Tuberville (R-AL)
$1K–$15K · Traded May 3, 2024 · disclosed Jun 14, 2024 · Joint
- May 23, 2024$1K–$15K
Sen. Gary C. Peters (D-MI)
$1K–$15K · Traded May 14, 2024 · disclosed May 23, 2024
Company context for SOLV
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
SOLV: third_quarter 2026 lobbying report
-Issues related to regulation of Ethylene Oxide (EtO). -Issues related to access to sterilization capacity for medical technologies. -Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and
Public: Oct 20, 2026, 10:48 PM EDTOriginal source ↗SOLV: third_quarter 2026 lobbying report
Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development. Issues related to budget reconciliation, appropriations, tax and trade policy; Issues related to Medical Device User Fee Amendments (MDUFA) reauthorization; Issues related to artificial intelligence; Issues related to medical, dental, and health information systems research and development.
Public: Oct 19, 2026, 7:42 PM EDTOriginal source ↗SOLV: second_quarter 2026 lobbying report
-Issues related to Department of Defense policy, procurement, and contracting processes for medical technology. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to domestic and global medical supply chain resilience. -Tariff issues generally. -Issues related to the 232 investigation of imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices. -Issues related to Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure to Impose and Effectively Enforce a Prohibition on
Public: Jul 20, 2026, 9:15 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.